This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The $406,611 award, effective April 1, 2025 through March 31, 2030, will enable researchers at the University of Texas Health Science Center at Houston to use patient-derived organoids to characterize GPR56's signaling mechanisms and role in cancer stem cell plasticity and metastasis. The project also aims to develop and evaluate highly potent GPR56-targeted antibody-drug conjugates, as well as assess combination therapies to overcome therapy resistance and metastasis in colorectal cancer. The proposed research seeks to reveal novel functions of GPR56 and generate unique targeted therapies to potentially improve treatment outcomes for colorectal cancer patients.
Generated 3/25/25, 4:50 AM